These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 36792608)
1. Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy. Zheng H; Peng X; Yang S; Li X; Huang M; Wei S; Zhang S; He G; Liu J; Fan Q; Yang L; Li H Cell Death Discov; 2023 Feb; 9(1):65. PubMed ID: 36792608 [TBL] [Abstract][Full Text] [Related]
2. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307 [TBL] [Abstract][Full Text] [Related]
3. Targeting tumor associated macrophages in hepatocellular carcinoma. Xu W; Cheng Y; Guo Y; Yao W; Qian H Biochem Pharmacol; 2022 May; 199():114990. PubMed ID: 35288152 [TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages in liver cancer: From mechanisms to therapy. Cheng K; Cai N; Zhu J; Yang X; Liang H; Zhang W Cancer Commun (Lond); 2022 Nov; 42(11):1112-1140. PubMed ID: 36069342 [TBL] [Abstract][Full Text] [Related]
6. Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma. Xiang X; Wang K; Zhang H; Mou H; Shi Z; Tao Y; Song H; Lian Z; Wang S; Lu D; Wei X; Xie H; Zheng S; Wang J; Xu X Cancer Immunol Res; 2024 Nov; 12(11):1603-1620. PubMed ID: 39115356 [TBL] [Abstract][Full Text] [Related]
7. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
8. Targeting tumor-associated macrophages: Novel insights into immunotherapy of skin cancer. Liu J; Lu J; Wu L; Zhang T; Wu J; Li L; Tai Z; Chen Z; Zhu Q J Adv Res; 2024 Jan; ():. PubMed ID: 38242529 [TBL] [Abstract][Full Text] [Related]
9. Targeting tumor-associated macrophages as an antitumor strategy. Cheng N; Bai X; Shu Y; Ahmad O; Shen P Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498 [TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy. Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395 [TBL] [Abstract][Full Text] [Related]
11. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Li Y; Xiang S; Pan W; Wang J; Zhan H; Liu S Front Oncol; 2023; 13():1166860. PubMed ID: 37064113 [TBL] [Abstract][Full Text] [Related]
12. The role of tumor-associated macrophage in breast cancer biology. Choi J; Gyamfi J; Jang H; Koo JS Histol Histopathol; 2018 Feb; 33(2):133-145. PubMed ID: 28681373 [TBL] [Abstract][Full Text] [Related]
13. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook. Zhou Z; Hu Y; Wu Y; Qi Q; Wang J; Chen L; Wang F Mol Immunol; 2022 Nov; 151():218-230. PubMed ID: 36179604 [TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Yin Y; Feng W; Chen J; Chen X; Wang G; Wang S; Xu X; Nie Y; Fan D; Wu K; Xia L Exp Hematol Oncol; 2024 Aug; 13(1):72. PubMed ID: 39085965 [TBL] [Abstract][Full Text] [Related]
15. Targeting tumor-associated macrophages for cancer immunotherapy. Cao X; Lai SWT; Chen S; Wang S; Feng M Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930 [TBL] [Abstract][Full Text] [Related]
16. Targeting tumor-associated macrophages for cancer treatment. Li M; He L; Zhu J; Zhang P; Liang S Cell Biosci; 2022 Jun; 12(1):85. PubMed ID: 35672862 [TBL] [Abstract][Full Text] [Related]
17. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications. Huang Q; Liang X; Ren T; Huang Y; Zhang H; Yu Y; Chen C; Wang W; Niu J; Lou J; Guo W Cell Oncol (Dordr); 2021 Jun; 44(3):525-539. PubMed ID: 33788151 [TBL] [Abstract][Full Text] [Related]
18. The Complexity of the Tumor Microenvironment in Hepatocellular Carcinoma and Emerging Therapeutic Developments. Argentiero A; Delvecchio A; Fasano R; Andriano A; Caradonna IC; Memeo R; Desantis V J Clin Med; 2023 Dec; 12(23):. PubMed ID: 38068521 [TBL] [Abstract][Full Text] [Related]
19. Promotion of epithelial-mesenchymal transformation by hepatocellular carcinoma-educated macrophages through Wnt2b/β-catenin/c-Myc signaling and reprogramming glycolysis. Jiang Y; Han Q; Zhao H; Zhang J J Exp Clin Cancer Res; 2021 Jan; 40(1):13. PubMed ID: 33407720 [TBL] [Abstract][Full Text] [Related]
20. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]